Skip to content

About Us:

Foundation News


About Us: Foundation News

The Spinal Muscular Atrophy Foundation Rings Nasdaq Opening Bell

August 18, 2018

The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…

Read More

Central and Peripheral Treatment of SMA meeting summary

November 20, 2017

On November 10th, the SMA Foundation held a meeting with over 100 SMA researchers, clinicians, and patient advocacy group representatives to discuss the potential impact of SMN upregulation outside of the central nervous system (CNS). The meeting focused on evidence from preclinical models and patients that indicate SMN has a role outside of the CNS…

Read More

Curis Lands $5.4M Spinal Muscular Atrophy Grant

September 7, 2004

Curis Inc., a Cambridge-based drug developer, received a $5.4 million three-year grant to help treat spinal muscular atrophy, the company announced Tuesday. The Spinal Muscular Atrophy Foundation awarded the grant to Curis to identify therapeutic compounds that could be used to treat the neuromuscular disease, which is the leading genetic cause of infant and toddler…

Read More

Curis Awarded $5.4M to Identify Treatment for Spinal Muscular Atrophy

September 7, 2004

Curis Inc. in Cambridge has received a $5.4 million, three-year grant from the Spinal Muscular Atrophy Foundation to identify therapeutic compounds to treat spinal muscular atrophy, a debilitating neuromuscular disease that is the leading genetic cause of infant and toddler death. The study will use proprietary Curis technologies and expertise to develop and refine motor…

Read More

The AAN Foundation and the SMA Foundation Announce the Recipients of the 2004 Young Investigator Award in SMA

April 19, 2004

New York, NY – April 19, 2004 – The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddlers. These grants support the implementation and advancement of clinical research…

Read More

Assay Designs, Inc. and the Spinal Muscular Atrophy Foundation announce collaboration

January 1, 1970

ANN ARBOR, Mich. — Sept. 15, 2008 – Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite drug discovery and development efforts for spinal muscular atrophy (SMA), the leading genetic cause of mortality in…

Read More
Scroll To Top